A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2014

At a glance

  • Drugs AVP 21D9 (Primary)
  • Indications Anthrax
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Emergent BioSolutions
  • Most Recent Events

    • 21 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Sep 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top